Clinical trials: Intravenous
Healthy
A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants
The purpose of this study is to learn if the study medicine (called PF-07264660) is safe and how it is processed in healthy Chinese participants. This study is seeking participants who: are between 18 to 65 years of age.
- Trial name
- NCT06712082
- Testing
- PF-07264660
- Where
- 2 sites in China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
I.V. Selonabant in Healthy Adult Subjects
This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Selonabant in Healthy Adult Subjects Aged 18 to 30 Years
- Trial name
- NCT07211607
- Testing
- selonabant
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Anebulo Pharmaceuticals
Alpha1-antitrypsin Deficiency, Healthy Volunteers
GLASSIA Infusion Rate Study
The purpose of this study was to generate sufficient safety and tolerability information in support of an increase in the infusion rate of intravenous GLASSIA in the prescribing information from 0.04 to 0.2 mL/kg/min.
- Trial name
- NCT01651351
- Testing
- Alpha1-proteinase inhibitor
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Baxalta now part of Shire
Healthy Volunteers (HV)
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KR25102 in Healthy Volunteers
Phase 1 Single Ascending Doses(SAD): Six cohorts of 53 healthy volunteers (HVs) will receive a single IV bolus injection of study drug or placebo.
- Trial name
- NCT07618156
- Testing
- KR25102 for Injection
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Invasive Aspergillosis
F901318 Single Ascending Dose Study in Healthy Male Volunteers
F901318 is a potent new antifungal agent for the treatment of systemic fungal infections. This study will test it for the first time in man with the objective of assessing its safety, tolerability and pharmacokinetic profile.
- Trial name
- NCT02142153
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Healthy
A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants
The purpose of the study is to assess the safety, pharmacokinetics (what the body does to the drug) and immunogenicity (ability of a particular substance to provoke an immune response in the human body) of CR6261 in Japanese…
- Trial name
- NCT02016066
- Testing
- CR6261
- Where
- Japan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Healthy
A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet
To investigate the absolute oral bioavailability of BI 730357 administered as tablet compared with [C-14]BI 730357 BS administered as intravenous microtracer
- Trial name
- NCT03804671
- Testing
- BI 730357, BI 730357 mixed with [C-14] BI 730357 BS
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Participants
A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants
This study will be conducted to evaluate a Single-Dose Subcutaneous (SC) Axatilimab Compared With Intravenous Axatilimab in Healthy Participants.
- Trial name
- NCT06713590
- Testing
- Axatilimab
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Diabetes Mellitus, Type 2
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
- Trial name
- NCT01300260
- Testing
- LY2189265, Insulin, Glucose
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
IgA Nephropathy
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject
The study is being conducted to Evaluate the Safety, Tolerability and Pharmacokinetics pharmacodynamics of SHR-2010 by intravenously/subcutaneously in Healthy Subject.
- Trial name
- NCT05398510
- Testing
- SHR-2010 injection
- Where
- China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Renal Impairment
A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment
This is a Phase 1, open label, single-dose, pharmacokinetic study to be conducted in male and female subjects with normal and impaired renal function.
- Trial name
- NCT02709382
- Testing
- Cefepime and Tazobactam combination
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Wockhardt
Healthy
A Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion
The purpose of this study is to evaluate the safety and tolerability of nemonoxacin in healthy Chinese volunteers.
- Trial name
- NCT01529957
- Testing
- Nemonoxacin Malate Sodium Chloride
- Where
- 26 sites in China
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Rheumatoid Arthritis
ALX-0061 Phase I Bioavailability Study in Healthy Volunteers
The overall aims of the study are: To assess the bioavailability of single doses of ALX-0061, administered s.c. at three dose levels, using 2 corresponding single i.v. dose levels as reference.
- Trial name
- NCT02101073
- Testing
- ALX-0061
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Ablynx, a Sanofi company
Healthy Volunteers, Bacterial Infections
Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects
RPX7009 (beta-lactamase inhibitor) is being studies in combination with a carbapenem biapenem to treat bacterial infections, including those due to multi-drug resistant bacteria.
- Trial name
- NCT01751269
- Testing
- RPX7009
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Healthy
Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects
The primary objective is to determine the safety and tolerability of the new IV formulation versus the current formulation of MOA-728 focusing on the theoretical potential for infusion-related and formulation-related…
- Trial name
- NCT00464802
- Testing
- MOA-728
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Healthy Male Participants
A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881
The purpose of this Phase I, open-label study is to evaluate the absorption, distribution, metabolism, excretion, absolute bioavailability, and to characterize the metabolites of AG-881 in healthy male participants following…
- Trial name
- NCT03960502
- Testing
- AG-881, [13C315N3]AG-881
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Agios Pharmaceuticals, Inc.
Healthy, Type 1 Diabetes
Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Autoimmune diseases happen when the immune system does not identify part of the body as belonging to it.
- Trial name
- NCT00896077
- Testing
- Lisofylline
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- DiaKine Therapeutics, Inc.
Healthy Adult Male
Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects
This is an open-label, single-dose, absorption, metabolism, excretion, and mass balance study following a single IV infusion of [14C]-VVZ-149 in healthy adult male subjects.
- Trial name
- NCT04415645
- Testing
- [14C]-VVZ-149
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Vivozon, Inc.
Healthy Volunteers
A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers
This study will compare the pharmacodynamics, pharmacokinetics and safety of efgartigimod as an intravenous infusion with efgartigimod as a subcutaneous injection in healthy adults.
- Trial name
- NCT04564066
- Testing
- efgartigimod IV, efgartigimod PH20 SC
- Where
- Netherlands
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- argenx
Healthy Volunteers
A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy
A Phase 1b/2a, Randomized, Multi-Center, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Oral SYN-004 on the Pharmacokinetics of Intravenous Ceftriaxone in Healthy Adult Subjects with a Functioning Ileostomy.
- Trial name
- NCT02419001
- Testing
- Period 1 - Treatment Sequence AB, Period 1 - Treatment Sequence AC, Period 2 - Treatment Sequence AB
- Where
- 3 sites in United States, Canada
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Theriva Biologics, Inc.